Previous 10 | Next 10 |
- Companies will partner to develop novel antibody-drug conjugates using NBE’s unique ADC platform - - Agreement encompasses an exclusive option on multiple targets over a two-year term, with potential to extend time and scope of the collaboration - - Deal is the fourt...
Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, wit...
FinancialBuzz.com News Commentary New York, NY (8/25/2020) – Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In particular, the top three diagnosed cancers accounted for over a third of total global cases. ...
– Submission based on the phase 3 pivotal CheckMate -9ER trial, which met its primary endpoint of significantly improving progression-free survival and secondary endpoints of overall survival and objective response rate – Exelixis, Inc. (NASDAQ:EXEL) today announced t...
Thus far in 2020, the only certainty for investors is uncertainty. The coronavirus disease 2019 (COVID-19) pandemic sent equities screaming to their fastest and steepest bear market correction in history during the first quarter, only to see stocks stage their strongest quarterly rally since 199...
Image source: The Motley Fool. Exelixis Inc (NASDAQ: EXEL) Q2 2020 Earnings Call Aug 6, 2020 , 5:30 p.m. ET Operator Continue reading
Exelixis, Inc. (EXEL) Q2 2020 Earnings Conference Call August 06, 2020 5:30 PM ET Company Participants Susan Hubbard – Executive Vice President of Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Senner – Chie...
Exelixis (NASDAQ: EXEL ) : Q2 Non-GAAP EPS of $0.25 beats by $0.11 ; GAAP EPS of $0.21 beats by $0.09 . More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Total Revenues of $259.5 Million, Cabozantinib Franchise Revenues of $178.7 Million - - GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.25 - - Conference Call and Webcast Today at 5:30 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial resu...
Exelixis (NASDAQ: EXEL ) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is $0.12 (-58.6% Y/Y) and the consensus Revenue Estimate is $226.4M (-5.8% Y/Y). Over the last 2 years, EXEL has beaten EPS estimates 100% of ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...